Physician

Samer Ballouz, M.D.

According to 2025 Medicare claims, Samer Ballouz, M.D. (NPI: 1528068020) practices medical oncology in the Warren-Troy-Farmington Hills, MI market, with the plurality of this provider's patient population coming from Oakland, MI. This provider's primary affiliated billing organization is MICHIGAN HEALTHCARE PROFESSIONALS PC (NPI: 1295023547; TIN: 451674932) and primary practice location at 48073-9998. Ballouz is affiliated with the Honest ACO of Michigan LLC (ACO ID: D0236), participating under the REACH model.

Ballouz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 671 traditional Medicare patients, billed 155,043 HCPCS/CPT codes, and received $2,582,634 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,705 prescription claims across 321 beneficiaries totaling $4,909,479 in drug costs, led by Xtandi (Enzalutamide). DME data shows 25 claims. Open Payments data shows 1 records totaling $525. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,775,516 and ending at $2,582,634. Concurrently, Part D prescription costs have risen steadily, from $1,522,111 to $4,909,479. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $2,895 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	639	142,777	$1,775,516
2016	790	140,892	$1,926,857
2017	858	132,148	$2,115,637
2018	811	178,085	$2,687,120
2019	900	165,330	$3,102,648
2020	718	147,266	$2,473,542
2021	713	155,062	$2,994,320
2022	711	175,518	$2,930,705
2023	663	170,896	$2,224,252
2024	671	155,043	$2,582,634

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	206	1,123	$1,522,111
2016	266	1,342	$2,897,867
2017	263	1,464	$2,754,641
2018	264	1,596	$3,872,819
2019	290	1,820	$4,521,175
2020	254	1,526	$4,502,546
2021	281	1,472	$4,012,375
2022	275	1,386	$3,854,667
2023	255	1,539	$4,919,751
2024	321	1,705	$4,909,479

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	26	$1,383
2016	N/R	40	$1,871
2017	N/R	N/R	N/R
2018	N/R	22	$871
2019	N/R	94	$9,315
2020	N/R	46	$2,770
2021	N/R	35	$1,497
2022	N/R	55	$1,914
2023	N/R	30	$4,966
2024	N/R	25	$508

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	206	612	$98
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	248	522	$69
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	156	551	$62
80047	Blood test, basic group of blood chemicals (calcium, ionized)	351	993	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	402	1,192	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	87	2,610	$1,144,546
Ibrance	Palbociclib	48	1,344	$762,745
Calquence	Acalabrutinib Maleate	39	1,170	$571,939
Lenalidomide	Lenalidomide	32	854	$541,203
Revlimid	Lenalidomide	18	504	$363,890

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$345
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$525	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Samer Ballouz, M.D.?

Tedicare shows public-source Medicare data for Samer Ballouz, M.D. (NPI 1528068020), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Samer Ballouz, M.D. have ACO affiliation data?

Samer Ballouz, M.D. is shown with ACO affiliation data for Honest ACO of Michigan LLC (REACH, ACO ID D0236).

What billing organization is linked to Samer Ballouz, M.D.?

Samer Ballouz, M.D. is linked to MICHIGAN HEALTHCARE PROFESSIONALS PC (billing NPI 1295023547) in the available physician profile data.

Does Samer Ballouz, M.D. have Open Payments data?

Samer Ballouz, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.